India's Symbiotec Pharmalab rises on US drug distribution deal
01/10/2026 07:17
BUZZ-India's Symbiotec Pharmalab rises on US drug distribution deal ** Shares of India's Symbiotec Pharmalab SYMI.NS rise 3.4% to 1,217.20 rupees
** Stock on track for fourth straight session of gains
** Symbiotec's unit Knovea Pharmaceutical enters into strategic commercialization agreement with global pharmaceutical company
** Says cannot disclose name of global pharmaceutical company due to "confidentiality obligations"
** SYMI says partner will commercialise and distribute two dual vial chamber-based injectable products in the US** Co says partnership opens commercial pathway in world's largest pharmaceutical market
(Reporting by Anushka Rajvedi in Bengaluru)
((mailto: anushka.rajvedi@thomsonreuters.com))
Recent news on Symbiotec Pharmalab
See all newsIndia's Symbiotec Pharmalab rises on US drug distribution deal
Brief: Symbiotec Pharmalab Unit Enters Into Strategic Commercialization Agreement
Brief: Symbiotec Pharmalab Receives U.S. FDA Eir For Pithampur Facility With Vai Status
India's Symbiotec Pharmalab declines after Q1 profit fall
India's Symbiotec Pharmalab rises after muted debut, valued at $779 million